DHAP方案治疗复发和难治性非何杰金氏恶性淋巴瘤的临床观察  

Effects of DHAP Regimen in Treatment of Relapsing and Refractory Non-Hodgkin’s Lymphoma

作　　者：何耀武[1] 胡国洪[1] 

机构地区：[1]清远市人民医院肿瘤防治中心放疗科,广东清远511500

出　　处：《国际医药卫生导报》2005年第10期22-23,共2页International Medicine and Health Guidance News

摘　　要：目的评价DHAP方案治疗复发和难治性非何杰金氏恶性淋巴瘤的疗效及毒性。方法采用DHAP方案治疗30例复发和难治性非何杰金氏恶性淋巴瘤,其中复发组20例,难治组10例。结果30例中完全缓解(CR)9例(30%),部分缓解(PR)7例(23.3%),总有效率为53.3%。有效患者中位缓解时间8.5个月。DHAP方案治疗后中位生存时间8.6个月,1年总生存率34.1%,2年总生存率18.5%。DHAP方案的不良反应主要表现为骨髓抑制,12例患者发生了白细胞减少引起的发热。结论DHAP方案治疗复发和难治性非何杰金氏恶性淋巴瘤的疗效是肯定的,毒性反应可以耐受,然而该方案的结果并不十分令人满意,仍需探索更好的高效低毒的治疗方案。Objective To evaluate the clinical results of DHAP regimen in treatment of relapsing and refractory non-Hodgkin’s lymphoma.Methods 30 patients with relapsing and refractory non-Hodgkin’s lymphoma(20 relapsing non-Hodgkin’s lymphoma patients,10 refractory non-Hodgkin’s lymphoma patients). Results The rate of complete remission was 30%, the rate of partial remission was 23.3%,and the overall response rate was 53.3%(the median remission was 8.5 months).Of all patients who were treated with DHAP regimen ,the median survival was 8.6 months. One and two years survival rate were 34.1% and 18.5%.The main side-effect was neutropenia,12 patients had fever from leukopenia. Conclusion DHAP regimen in treatment of the patients with relapsing and refractory non-Hodgkin’s lymphoma was positive .It’s toxicity was toletable .However ,it need to search more effective and safety regimens.

关 键 词：非何杰金氏恶性淋巴瘤 DHAP方案 化学治疗 

分 类 号：R733.1[医药卫生—肿瘤]